Celldex Therapeutics
CLDX
144 hedge funds and large institutions have $1.39B invested in Celldex Therapeutics in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 61 increasing their positions, 42 reducing their positions, and 20 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 42
2% more call options, than puts
Call options by funds: $17.2M | Put options by funds: $16.9M
0.79% more ownership
Funds ownership: 106.22% → 107.01% (+0.79%)
4% less funds holding
Funds holding: 150 → 144 (-6)
18% less capital invested
Capital invested by funds: $1.7B → $1.39B (-$311M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$18.8M |
| 2 |
Morgan Stanley
New York
|
+$12.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.42M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$7.8M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$7.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$40.8M |
| 2 |
State Street
Boston,
Massachusetts
|
-$13.6M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$7.15M |
| 4 |
EP
Eversept Partners
New York
|
-$6.19M |
| 5 |
FAM
Fred Alger Management
New York
|
-$5.61M |
CLDX Hedge Fund Activity: Q3 2023 in Review
144 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2023, worth a combined $1.39B — down 18% from $1.7B a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CLDX and 15 opened new positions — a net loss of 5 holders — while 42 trimmed existing stakes and 61 added.
The largest buyer was Kynam Capital Management, adding an estimated $18.8M. The largest seller was Jennison Associates, cutting an estimated $40.8M.
- 144 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2023, down from 150 in Q2 2023.
- Funds reported $1.39B of Celldex Therapeutics stock for Q3 2023, down 18% quarter-over-quarter.
- 15 funds opened new Celldex Therapeutics positions in Q3 2023 and 20 closed out, a net change of -5 holders.
- The largest Celldex Therapeutics buyer in Q3 2023 was Kynam Capital Management, an estimated $18.8M added.
- The largest Celldex Therapeutics seller in Q3 2023 was Jennison Associates, an estimated $40.8M sold.
Based on aggregated 13F filings for Q3 2023.